Nachrichten zur ARCTIC BIOSCIENCE NK -,10 Aktie

Arctic Bioscience will publish its Q1 2026 operational update on Thursday 30[th] of April 2026, at 07:00 CET.The same day…

Reference is made to the stock exchange release published by Arctic Bioscience 9th December 2025 regarding exercise of right to…

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. An…

12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per…

The Annual General Meeting of Arctic Bioscience AS was held Monday 26 May 2025 at 11:00 (CET). All the items…

Reference is made to the stock exchange release published by Arctic Bioscience 8th May 2025 regarding Board approval of share…

Reference is made to the stock exchange release published by Arctic Bioscience 28th April 2025 regarding exercise of right to…

The HeROPA phase 2b study in mild-to-moderate psoriasis show encouraging results on key secondary endpoint with increasing durable efficacy up…

Reference is made to the stock exchange release published by Arctic Bioscience 30th January 2025 regarding exercise of right to…

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. A…

Reference is made to the stock exchange release from earlier today, 13[th] January 2025, regarding new funding, including a convertible…

· Arctic Bioscience is now funded through a NOK 30 million loan facility. · Strong 30% y/y growth in…

An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 19 November 2024 at 10:00 (CET). All the items…

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 19 November 2024 at 10:00 (CET), as a…

Highlights Q3 2024: · The HeROPA 6-month read-out showed an effect close to the assumed effect level in the…

Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK…

With reference to yesterday’s stock exchange release regarding webcast to be hosted today at 12:00 CET to present the results…

Arctic Bioscience are today presenting new research on cells at the EADV congress in Amsterdam. These cellular data show anti-psoriatic…

Arctic Bioscience will publish its financial results for the first half year of 2024 on Thursday 29[th] of August, at…

Arctic Bioscience are today presenting a new data on anti-inflammatory cellular functions of herring roe oil at the 9th European…

Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as…

The Annual General Meeting of Arctic Bioscience AS was held Friday 26 April 2024 at 11:00 (CET). All the items…

Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting. Shareholders…

Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements. The report…

The Board of Directors of Arctic Bioscience AS has resolved to extend the share option agreements for the following members…

Highlights Q4 2023: · The HeROPA clinical trial fully recruited in January 2024 · Available liquidity end of…

With reference to the stock exchange announcement from 17. January 2024 which reported that the HeROPA phase IIb clinical trial…